A newly developed validated Investigator Global Assessment (IGA) atopic dermatitis (AD) scale, accompanied by a training video, demonstrated strong reliability for assessing severity of AD in study research published in the Journal of the American Academy of Dermatology.

A total of 24 global academic and industry dermatologists with expertise in AD formed an advisory group to develop the validated IGA AD (vIGA-ADâ„¢) scale. The scale developed by the expert dermatologists measured improvement in clinical signs of AD, which represents the priority domain in drug registration studies. Clinical signs included erythema, lichenification, induration/papulation, and oozing/crusting. Morphological descriptors, as recommended by the FDA, described clearly distinct categories for clear (absence of disease), almost clear (IGA score of 1), and mild disease (IGA score of 2).